Cough - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Cough - Pipeline Review, H2 2016

Cough - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Cough - Pipeline Review, H2 2016
Published Aug 31, 2016
96 pages — Published Aug 31, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Cough - Pipeline Review, H2 2016, provides an overview of the Cough pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cough and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cough
- The report reviews pipeline therapeutics for Cough by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cough therapeutics and enlists all their major and minor projects
- The report assesses Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cough

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cough
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the mos

  
Source:
Document ID
GMDHC8422IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Cough Overview91
Therapeutics Development102
  Pipeline Products for Cough Overview101
  Pipeline Products for Cough Comparative Analysis111
Cough Therapeutics under Development by Companies122
Cough Therapeutics under Investigation by Universities/Institutes141
Cough Pipeline Products Glance154
  Late Stage Products151
  Clinical Stage Products161
  Early Stage Products171
  Unknown Stage Products181
Cough Products under Development by Companies191
Cough Products under Investigation by Universities/Institutes201
Cough Companies Involved in Therapeutics Development2118
  Afferent Pharmaceuticals, Inc.211
  Alitair Pharmaceuticals, Inc.221
  Alveonix AG231
  AstraZeneca Plc241
  AusBio Ltd251
  Charleston Laboratories, Inc.261
  Conrig Pharma ApS271
  Daewoong Pharmaceutical Co., Ltd.281
  GlaxoSmithKline Plc291
  Glenmark Pharmaceuticals Ltd.301
  GW Pharmaceuticals Plc311
  Hyundai Pharmaceutical Co., Ltd.321
  Johnson &Johnson331
  NeRRe Therapeutics Ltd341
  Orbis Biosciences Inc351
  Patara Pharma, Inc.361
  Pila Pharma AB371
  Vernalis Plc381
Cough Therapeutics Assessment399
  Assessment by Monotherapy Products391
  Assessment by Combination Products401
  Assessment by Target412
  Assessment by Mechanism of Action432
  Assessment by Route of Administration452
  Assessment by Molecule Type471
Drug Profiles4833
  Ax-8 Drug Profile481
  benzonatate Drug Profile491
  CCP-05 Drug Profile501
  CCP-06 Drug Profile511
  CCP-07 Drug Profile521
  CCP-08 Drug Profile531
  CLAT-313 Drug Profile541
  codeine + guaifenesin Drug Profile551
  cromolyn sodium Drug Profile561
  DWJ-1340 Drug Profile571
  GRC-17536 Drug Profile582
  GSK-2339345 Drug Profile601
  guaifenesin + hydrocodone Drug Profile611
  guaifenesin ER Drug Profile621
  JNJ-39729209 Drug Profile631
  lesogaberan Drug Profile641
  levodropropizine CR Drug Profile651
  MD-990 Drug Profile661
  MK-7264 Drug Profile674
  NEO-5937 Drug Profile711
  orvepitant maleate Drug Profile722
  S-1226 Drug Profile742
  Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders Drug Profile761
  Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases Drug Profile771
  ST-015 Drug Profile781
  XEND-0501 Drug Profile792
Cough Dormant Projects813
Cough Discontinued Products841
Cough Product Development Milestones8510
  Featured News &Press Releases851
    Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study851
    May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference852
    May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors871
    Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference881
    Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study881
    Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study881
    Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study891
    Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing891
    Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial901
    Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine911
    Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing911
    Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet912
    Sep 09, 2014: Charleston Laboratories Announces Key Clinical Updates for Novel Drug931
    Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept931
    Apr 29, 2014: Second Product in Vernalis Cough Cold Pipeline Achieves Proof-of-Concept932
Appendix952
  Methodology951
  Coverage951
  Secondary Research951
  Primary Research951
  Expert Panel Validation951
  Contact Us951
  Disclaimer961

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Cough - Pipeline Review, H2 2016" Aug 31, 2016. Alacra Store. May 14, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cough-Pipeline-Review-H2-2016-2088-16505>
  
APA:
Global Markets Direct - Market Research. (2016). Cough - Pipeline Review, H2 2016 Aug 31, 2016. New York, NY: Alacra Store. Retrieved May 14, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Cough-Pipeline-Review-H2-2016-2088-16505>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.